

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




FIG.1

Malignant Breast  
96102003G H9C65




FIG.2A

Malignant Breast  
9609C033R H9C65




FIG.2B

Normal Breast.  
9712C030G H9C65



FIG.2C

MB8 Cell Line  
H9C65




FIG.2D

Malignant Breast  
96102003G H95C30




FIG.3A

Malignant Breast  
9609C033R H95C30




FIG.3B

Normal Breast  
9712C030G H95C30



FIG.3C

MB8 Cell Line  
H95C30




FIG.3D

4/25




FIG.4A





FIG.4B

5/25


1 2 3 4 3



anti-Mam PAb 10931

FIG.4C

6/25



anti-myc MAb

FIG.5A





FIG.5B

7/25

1	2	3	4
1 2	1 2	1 2	1 2



10918 10923 11543 10931

FIG.6A

5	6	7	8
1 2	1 2	1 2	1 2




H85 H68 H111 myc

FIG.6B



8/25

9	10	11	12
1 2	1 2	1 2	1 2




10918 10923 11543 10931

Polyclonal Antisera, 1:5000

**FIG.6C**

13	14	15	16
1 2	1 2	1 2	1 2



H85 H68 H111 myc

Monoclonal Antibodies 1:50

**FIG.6D**

9/25

1 2



FIG.7

10/25




FIG. 8A




FIG. 8B

11/25




FIG.9




FIG. 10

13/25

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15




FIG. 11A

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15






FIG. 11B

14/25



anti-BU101.3, 10923, 1:5000  
sample reduced and boiled


FIG.12A



anti-MAM.1, 10931, 1:5000  
sample reduced and boiled

FIG.12B

15/25




Polyclonal Antibody 10923  
anti-BU101.3

FIG.13A



16/25


Reduced								Not Reduced							
42	43	44	45	46	47	48	42	43	44	45	46	47	48		



Polyclonal Antibody 10931  
anti-MAM.1


FIG.13B

17/25




anti-BU101 polyclonal 10923

FIG.14A



anti-Mam polyclonal

FIG.14B



anti-myc, 1:5000

FIG.15

19/25

Met	Lys	Leu	Ser	Val	Cys	Leu	Leu	Leu	Val	Thr	Leu	Ala	Leu	Cys	Cys
1				5					10					15	
Tyr	Gln	Ala	Asn	Ala	Glu	Phe	Cys	Pro	Ala	Leu	Val	Ser	Glu	Leu	Leu
			20					25					30		
Asp	Phe	Phe	Phe	Ile	Ser	Glu	Pro	Leu	Phe	Lys	Leu	Ser	Leu	Ala	Lys
		35					40					45			
Phe	Asp	Ala	Pro	Pro	Glu	Ala	Val	Ala	Ala	Lys	Leu	Gly	Val	Lys	Arg
	50					55					60				
Cys	Thr	Asp	Gln	Met	Ser	Leu	Gln	Lys	Arg	Ser	Leu	Ile	Ala	Glu	Val
65				70					75					80	
Leu	Val	Lys	Ile	Leu	Lys	Lys	Cys	Ser	Val						
			85					90							

FIG.16

## ASSEMBLY OF BS106 FROM INDIVIDUAL EXPRESSED TAGS




FIG.17

>BS106 CONSENSUS

CGGCTCGAGCTCTTAGGCTTTGAAGCATTTTTGTCTGTGCTCCCT  
 GATCTTCAGGTCACCACCATGAAGTTCTTAGCAGTCCTGGTACTC  
 TTGGGAGTTTCCATCTTTCTGGTCTCTGCCCAGAATCCGACAACA  
 GCTGCTCCAGCTGACACGTATCCAGCTACTGGTCCTGCTGATGAT  
 GAAGCCCCTGATGCTGAAACCACTGCTGCTGCAACCACTGCGACC  
 ACTGCTGCTCCTACCACTGCAACCACCGCTGCTTCTACCACTGCT  
 CGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTTCCG  
 AATGGTAGAGTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTG  
 CAATTGGTCACAACTATTCATGCTTCCTGTGATTTTCATCCAATA  
 CTTACCTTGCCTACGATATCCCCTTTATCTCTAATCAGTTTATTT  
 TCTTCAAATAAAAAATAACTATGAGCAACATAAAAAAAAAAAAAA




FIG.18A


>BS106 TRANSLATION

MKFLAVLVLLGVSI FLVSAQNPTTAAPADTYPATGPADDEAPDAE  
 TTAAATTATTAAPTATTAASTTARKDIPVLPKWVGDLPNGRVCP

FIG.18B


22/25





Anti-BU101.3 Polyclonal


FIG.20A



Anti-Mam.1 Polyclonal


FIG.20B





Anti-BU101.3 Polyclonal

FIG.20C



Anti-Mam.1 Polyclonal

FIG.20D

Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mammaglobin	CK19	
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)	N=95
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)	N=90
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)	N=85
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)	N=85
ER	-0.18 (NS)	-0.10 (NS)	<b>-0.23 (p=0.02)</b>	-0.18 (NS)	N=99
PR	-0.18 (NS)	-0.10 (NS)	<b>-0.23 (p=0.02)</b>	-0.18 (NS)	N=99
HER2	-0.12 (NS)	<b>0.36 (p=0.003)</b>	0.11 (NS)	0.02 (NS)	N=67
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)	N=77
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS)	N=101
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)	N=101
Mamm	0.37 (p=0.0001)	0.004 (NS)	-----	0.07 (NS)	N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. NS=not significant

FIG.21